New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase... ( Results Presented at the ADA...)

New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study

Date:6/7/2008

Results Presented at the ADA's Annual Scientific Sessions

SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the results of the dose-finding study for its new injectable diabetes compound AVE0010, a GLP-1 agonist, were presented at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions meeting in San Francisco, California.

The study found that AVE0010 was well tolerated and significantly improved glycemic control versus placebo in type 2 diabetes patients inadequately controlled with metformin alone. The once daily regimen demonstrated a clear dose response with a similar HbA1c reduction to twice daily regimen. AVE0010 was also found to be associated with weight loss and reductions in postprandial glucose.

"The results of the once daily AVE0010 regimen are very promising and this new GLP-1 agonist has a potential to become an important addition to the treatment armamentarium for type 2 diabetes," said Robert Ratner, from the MedStar Research Institute Washington DC, Principal Investigator of the dose-finding study.

About the Study

The dose-finding study involved 542 type 2 diabetes patients inadequately controlled on metformin monotherapy (1.6-1.9 g/day). In this double-blind study, patients were randomized to receive for 13 weeks, either AVE0010 subcutaneously at the doses of 5, 10, 20 and 30 micron(g) once daily or twice daily, or placebo. The primary endpoint was change in HbA1c from baseline. Secondary endpoints included weight change and 2-hour post-prandial plasma glucose (PPG).

Baseline characteristics were similar among groups in terms of mean age (56 +/-9 years), diabetes duration (6.6 +/-5 years), HbA1c (7.5 +/-0.6%) and Body Mass Index (31.9 +/-4 kg/m2). Despite mildly elevated baseline HbA1c, the results of the study demonstrated a highly statistically significant dose response with a net decrease in mean HbA1c from baseline subtracted from placebo f
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
2. DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
3. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
4. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
5. International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India
6. Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
7. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
8. Continued Funding to Help Advance Exciting Moment in Diabetes Research
9. CureDMs Diabetes Therapy Achieves Major Development Milestone
10. Drug Combo Could Lower Diabetes Complications and Costs
11. Discovery Leads to Earlier Diagnosis of Type 1 Diabetes

Post Your Comments:

New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase...( Results Presented at the ADA...),Health